Dipal Doshi is listed as an executive officer and director on 3 SEC Form D filings by 1 issuer between Dec 2018 and Apr 2021: Entrada Therapeutics, Inc. (Boston, MA — biotechnology — 2018–2021; $116.2M reported sold to 26 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Kush Parmar (3 shared filings), Natarajan Sethuraman (3 shared filings), Anja Harmeier (2 shared filings), John F. Crowley (2 shared filings), Louis Tartaglia (2 shared filings) and 9 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Dipal. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 3 public filings for Dipal Doshi and found 2 differences: No amendment in the last 12 months on an offering that may still be open; Industry group changed between filings.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.